Harbin Pharmaceutical Group Co., Ltd. has a brand of three well -known markets with San Jing, Harbin Pharmaceutical, Gai Zhonglong, Stomach British, Hu Tong, Shi Yitang, with Harbin Pharmaceutical General Plant, Harbin Pharmaceutical Sanjing, Harbin Pharmaceutical Six Factory, and Harbin Pharmaceutical Six Factory, and Harbin Pharmaceutical Six Factory, and Harbin Pharmaceutical Six Factory.Harbin Pharmaceutical Chinese Medicine Company, Harbin Pharmaceuticals, Harbin Pharmaceutical Vaccine and other well -known domestic pharmaceutical manufacturing companies, Harbin Pharmaceutical Co., Ltd. and people Tongtai listed companies.
Harbin Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Harbin Pharmaceutical Group") is a Sino -foreign joint venture.State -owned shares account for 45%, CITIC Capital Iceland Investment Co., Ltd. and Huaping Iceland Investment Co., Ltd. each hold 22.5%, and Harbin State -owned Enterprise Reorganization Management Consulting Co., Ltd. holds 10%.Harbin SASAC is the largest shareholder.Has Harbin Pharmaceutical and Peoples Tongtai listed companies.As of the end of 2014, the total assets of Harbin Pharmaceutical Group were 19 billion yuan, fixed assets were 4.8 billion yuan, and net assets were 11.1 billion yuan.There are currently 28,300 employees.There are 3222 titles above the middle level and 6,163 bachelor degree or above.Harbin Pharmaceutical Group mainly covers the six major business segments of antibiotics, non -prescription drugs and health products, traditional and modern Chinese medicine, biomedicine, animal vaccine and pharmaceutical business.Has Harbin Pharmaceutical General Plant, Harbin Pharmaceutical San Jing, Harbin Pharmaceutical Six Factory, Harbin Pharmaceutical Chinese Medicine Company, Harbin Pharmaceutical Bio, Harbin Pharmaceutical Vaccine and other well -known domestic pharmaceutical manufacturing companies and Harbin Pharmaceutical Peoples Tongtai, Harbin Pharmaceutical Marketing Co., Ltd., Harbin Pharmaceutical SalesCommercial circulation enterprises such as Co., Ltd..Has five famous Chinese trademarks with "Harbin Pharmaceutical", "Three Essence", "Gai Zhong Gai", "Hu Tong" and "Shitangtang".After evaluation, the brand value of only "Harbin Pharmaceutical" reached 20.611 billion yuan.The domestic market share of antibiotics leading products of cephalosporin sodium sodium, cephalosporium sodium noodles, and powder needles are above 35%, ranking first in the same industry; calcium supplement preparation production and sales are close to half of the countrys total market.There are 1995 product approval and 22 dosage forms.Among them, there are 600 products and 69 exclusive products.In 2014, there were 83 varieties with sales revenue, of which 22 varieties with sales revenue exceeded 100 million yuan.With an annual output of 15,000 tons, a chemical pink pinrse of 2 billion, 80 million pink pouring agents, 2.1 billion pads of oral solution, 10 billion tablets, capsules of 13.4 billion capsules, 2 billion pockets of chemical drugs, animal vaccine vaccines, animal vaccines32 billion head/mm/ml of production capacity.Harbin Pharmaceutical Group ranked fourth and fifth in the selection of Top 100 Chinese Pharmaceutical Industry Enterprises hosted by the Southern Medical Economic Research Institute hosted by the State Food and Drug Administration in 2013 and 2014, respectively.In 2014, the OTC brand enterprise comprehensive ranking of OTC brand enterprises held in 2014 ranked sixth.Harbin Pharmaceutical Group has established more than 130 sales offices in more than 30 major cities across the country, and has more than 1,000 retail chain pharmacies and counters. It has formed a widely -covered and functional marketing network.In terms of international marketing, varieties such as cephalosporte sodium, cephalosporin sodium, cephalosporin, penicillin sodium, ammonia sodium sodium and other varieties have completed product registration in Russia, and become the most registered pharmaceutical companies in Russia in my country to form a multi -product marketing portfolio Good situation, export more than 100 million US dollars per year.While strengthening the marketing strategy, Harbin Pharmaceutical Group also invested 180 million yuan to build a new drug research and development base covering an area of ??40,000 square meters and a construction area of ??38,000 square meters -Harbin Pharmaceutical Group Pharmaceutical Research Institute.There are 5 R & D centers in biopharmaceuticals, chemicals, chemicals, chemical preparations, Chinese medicine and health products, and quality testing and analysis.It has a Chinese test base and an industrialization platform, as well as advanced scientific research instruments and equipment worth nearly 50 million yuan.Through the internal and external methods, a number of new R & D platforms such as the slowly controlled interpretation of the osmotic interpretation technology platform, the lipid milk fat body fat microsphere technology platform, the biological PEGization technology platform, involved anti -tumor, cardiovascular and cerebral blood vessels, circulatory systemsIn many treatment areas such as the digestive system, it continuously provides a strong innovation driving force for the sustainable development of Harbin medicine.